Multiple clinical trials within the past decade have aimed to study the safety and efficacy of various probiotic strains in treating patients with irritable bowel syndrome (IBS). However, there exists much heterogenicity in study design among these trials, namely, in bacterial strain, dose, dosage form, sample size, study duration, and population demographics.
Aim:
The aim of this study was to identify the shortcomings of clinical trials using probiotic treatments in subjects with IBS, so that researchers may realize where limitations exist, allowing them to curtail these limitations in future trials.
Methods:
An extensive PubMed search was conducted using the following keywords: probiotics in irritable bowel syndrome, probiotic pharmacokinetics, Lactobacillus, Bifidobacterium, Alosetron, Tegaserod, Alosetron, and Tegaserod safety profile. A total of 62 articles were used in constructing this review, with 20 original articles.
Results:
Stark differences in study design existed among the 20 original articles analyzed, as well as an outstandingly high “placebo effect,” making the ability to compare these articles as a means for evidence-based treatment therapy in IBS very difficult.
Conclusions:
Future large, randomized, double-blind, placebo-controlled clinical trials must be conducted, embodying minimal variability in study designs, to appropriately assess the efficacy of specific probiotic strains over placebo.
Get full access to this article
View all access options for this article.
References
1.
NiedzielinK, KordeckiH, BirkenfeldB. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol, 2001; 13:1143–1147.
2.
BommelaerGet al.Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol Clin Biol, 2004; 28,6-7 pt 1:554–561.
3.
ReyE, TalleyNJ. Irritable bowel syndrome: Novel views on the epidemiology and potential risk factors. Dig Liver Dis, 2009; 41:772–780.
4.
BrandtLJet al.Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol, 2002; 97,11 suppl:S7–S26.
5.
GuyonnetDet al.Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther, 2007; 26:475–486.
6.
Di PiroJTet al.Pharmacotherapy: A Pathophysiologic Approach, 7th. New York: McGraw-Hill Companies, 2008.
7.
BarbaraGet al.Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology, 2004; 126:693–702.
8.
RousseauxCet al.Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med, 2007; 13:35–37.
9.
BalsariAet al.The fecal microbial population in the irritable bowel syndrome. Microbiologica, 1982; 5:185–194.
10.
SiJMet al.Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol, 2004; 10:1802–1805.
11.
MalinenEet al.Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol, 2005; 100:373–382.
JohanssonMLet al.Administration of different Lactobacillus strains in fermented oatmeal soup: In vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol, 1993; 59:15–20.
14.
O'MahonyLet al.Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology, 2005; 128:541–551.
TornblomHet al.Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology, 2002; 123:1972–1979.
17.
ChadwickVSet al.Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology, 2002; 122:1778–1783.
18.
LigaardenSCet al.A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: A randomised controlled trial. BMC Gastroenterol, 2010; 10:16.
19.
Drouault-HolowaczSet al.A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol, 2008; 32:147–152.
20.
PatelSMet al.The placebo effect in irritable bowel syndrome trials: A meta-analysis. Neurogastroenterol Motil, 2005; 17:332–340.
21.
PitzM, CheangM, BernsteinCN. Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol, 2005; 3:237–247.
22.
O'SullivanMA, O'MorainCA. Bacterial supplementation in the irritable bowel syndrome: A randomised double-blind placebo-controlled crossover study. Dig Liver Dis, 2000; 32:294–301.
23.
WhorwellPJet al.Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol, 2006; 101:1581–1590.
24.
ChangJY, TalleyNJ. Current and emerging therapies in irritable bowel syndrome: From pathophysiology to treatment. Trends Pharmacol Sci, 2010; 31:326–334.
25.
BrennerDMet al.The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. Am J Gastroenterol, 2009; 104:1033–1049quiz 1050.
26.
CamilleriM. Probiotics and irritable bowel syndrome: Rationale, mechanisms, and efficacy. J Clin Gastroenterol, 2008; 42,suppl 3 pt 1:S123–S125.
27.
QuigleyEM. Probiotics in functional gastrointestinal disorders: What are the facts?Curr Opin Pharmacol, 2008; 8:704–708.
28.
KimHJet al.A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther, 2003; 17:895–904.
29.
KimHJet al.A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil, 2005; 17:687–696.
30.
NobaekSet al.Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol, 2000; 95:1231–1238.
31.
MartoniCet al.Microencapsulated bile salt hydrolase producing Lactobacillus reuteri for oral targeted delivery in the gastrointestinal tract. Appl Microbiol Biotechnol, 2008; 81:225–233.
32.
BegleyM, HillC, GahanCG. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol, 2006; 72:1729–1738.
33.
ZengJet al.Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther, 2008; 28:994–1002.
34.
KajanderKet al.A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention. Aliment Pharmacol Ther, 2005; 22:387–394.
35.
SimrenMet al.Clinical trial: The effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome: A randomized, double-blind, controlled study. Aliment Pharmacol Ther, 2010; 31:218–227.
36.
EnckPet al.A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome: A randomized controlled trial with primary care physicians. Neurogastroenterol Motil, 2008; 20:1103–1109.
37.
HongKSet al.Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. Gut Liver, 2009; 3:101–107.
38.
WilliamsEA, StimpsonJ, WangDet al.Clinical trial: A multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther, 2009; 29:97–103.
39.
Rome Foundation. 2010[cited November 23, 2010]www.romecriteria.org/criteria/. 2010 November 23.
40.
SinnDHet al.Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci, 2008; 53:2714–2718.
41.
DolinBJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol, 2009; 31:655–659.
42.
GawronskaAet al.A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther, 2007; 25:177–184.
43.
AndriulliAet al.Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: A multicenter, randomized study. J Clin Gastroenterol, 2008; 42,suppl 3 pt 2:S218–S223.
44.
ChassanyOet al.Validation of a specific quality of life questionnaire for functional digestive disorders. Gut, 1999; 44:527–533.
45.
HaysRD, SherbourneCD, MazelRM. The RAND 36-Item Health Survey 1.0. Health Econ, 1993; 2:217–227.
46.
FrancisCY, MorrisJ, WhorwellPJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther, 1997; 11:395–402.
47.
HeatonKWet al.Defecation frequency and timing, and stool form in the general population: A prospective study. Gut, 1992; 33:818–824.
48.
SternbachRA. The effects of instructional sets on autonomic responsivity. Psychophysiology, 1964; 1:67–72.
49.
LewisJH. Alosetron for severe diarrhea-predominant irritable bowel syndrome: Safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol, 2010; 4:13–29.
50.
JohnsonFRet al.Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes. Value Health, 2010; 13:418–423.
51.
LoughlinJet al.Tegaserod and the risk of cardiovascular ischemic events: An observational cohort study. J Cardiovasc Pharmacol Ther, 2010; 15:151–157.
52.
AndersonJLet al.Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case–control study. J Cardiovasc Pharmacol Ther, 2009; 14:170–175.
53.
HaslerWL, SchoenfeldP. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome. Drug Saf, 2004; 27:619–631.
54.
Tegaserod Clinical Research Group. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome [in Chinese]Zhonghua Nei Ke Za Zhi, 2003; 42:88–90.
55.
Al-JudaibiB, ChandeN, GregorJ. Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation. Can J Clin Pharmacol, 2010; 17:e194–e200.
56.
BustiAJ, MurilloJRJr, CryerB. Tegaserod-induced myocardial infarction: Case report and hypothesis. Pharmacotherapy, 2004; 24:526–531.
57.
SmithTJ, MargolisLM, YoungAJ. Should military dining facilities offer and promote consumption of probiotic-containing foods?Military Med, 2010; 175:770–783.
